Liposarcoma Pipeline 2025: Clinical Trials, Revenue Share, Medication, Treatment Drugs, Companies by DelveInsight

Liposarcoma companies are Karyopharm Therapeutics, Rain Therapeutics, Pfizer, Sanofi, Incyte Corporation, Macrogenics, Adaptimmune, Merck KGaA, GlaxoSmithKline, Novartis Oncology, Immune Design, Syndivia, TerSera Therapeutics, among others.
Liposarcoma Pipeline Summary

Around 15+ companies are developing therapies, with Boehringer Ingelheim's Brigimadlin being the most advanced (Phase III). The report categorizes ~20+ products by phase (late, mid, early), route of administration (oral, parenteral, intravitreal, etc.), and molecule type (monoclonal antibodies, peptides, small molecules, gene therapies, etc.), providing a comprehensive therapeutic assessment.

DelveInsight's report, "Liposarcoma Pipeline Insight 2025" offers an extensive overview of more than 15 companies and over 15 drugs in the Liposarcoma pipeline. The report includes detailed profiles of Liposarcoma pipeline drugs, covering both clinical trials and preclinical stage candidates. It also evaluates the pipeline therapeutics based on product type, development stage, route of administration, and molecule classification. Additionally, the report identifies inactive pipeline products within the Liposarcoma space. Within the report, each drug is thoroughly described, including its mechanism of action, details of clinical trial studies, any NDA approvals, and ongoing product development activities. These activities encompass technology platforms, collaborations, licensing agreements, mergers and acquisitions, funding status, designations, and other relevant product information.

Unlock key insights into the Liposarcoma treatment landscape with DelveInsight's "Liposarcoma Pipeline Insight 2025" report. Discover detailed drug profiles, clinical trial updates, and market opportunities across 15+ companies and therapies. Don't miss out-access the full report now to stay ahead in this evolving field! @ Liposarcoma Pipeline Outlook [https://www.delveinsight.com/report-store/liposarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Key takeaways from the Liposarcoma Pipeline Report

* More than 15 companies are actively developing over 15 pipeline therapies for Liposarcoma, and their successful market introduction is expected to significantly boost industry revenue.
* In March 2025, a multicenter, open-label, non-randomized clinical trial enrolled patients with locally advanced or metastatic soft tissue sarcoma who had shown disease progression within six months before joining the study.
* Ascentage Pharma Group Inc. reported Phase Ib/II trial results in March 2025 for APG-115 combined with a PD-1 inhibitor in patients with advanced Liposarcoma and other solid tumors.
* Boehringer Ingelheim announced findings from the Brightline-4 study in March 2025, a Phase III open-label, single-arm, multicenter trial evaluating Brigimadlin (BI 907828) in both treatment-naive and previously treated advanced dedifferentiated Liposarcoma patients.
* In January 2025, Adaptimmune Therapeutics plc revealed that letetresgene autoleucel (lete-cel) received breakthrough therapy designation from the U.S. FDA for patients with unresectable or metastatic myxoid/round cell Liposarcoma, positive for specific HLA types, and whose tumors express the NY-ESO-1 antigen.
* Leading companies in the Liposarcoma space include Karyopharm Therapeutics, Rain Therapeutics, Pfizer, Sanofi, Incyte Corporation, Macrogenics, Adaptimmune, Merck KGaA, GlaxoSmithKline, Novartis Oncology, Immune Design, Syndivia, TerSera Therapeutics, among others.
* Prominent therapies in the Liposarcoma pipeline include Trabectedin, Dexamethasone, Dacarbazine, RAIN-32, HDM201, LEE011, Selinexor, IPI-504, Yondelis, Cabazitaxel, MGCD516, and others.
* Both industry players and academic researchers are actively evaluating challenges and exploring opportunities to advance Liposarcoma research and development, with a focus on innovative treatment strategies to improve patient outcomes.

Stay ahead in Liposarcoma innovation! Explore our detailed report on 15+ companies and breakthrough therapies shaping the future of treatment. Don't miss key clinical trial updates and market insights-get your copy today to drive strategic growth and investment decisions. @ Liposarcoma Clinical Trials and FDA Approvals [https://www.delveinsight.com/sample-request/liposarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Liposarcoma Overview

Liposarcoma is a rare type of cancer that arises in fat cells, typically developing in deep soft tissues such as those in the thighs, behind the knees, or in the abdomen. It belongs to a broader group of cancers known as soft tissue sarcomas. Liposarcoma can vary widely in its aggressiveness and clinical behavior depending on the subtype, which includes well-differentiated, dedifferentiated, myxoid, round cell, and pleomorphic forms. Well-differentiated liposarcomas tend to grow slowly and have a lower risk of metastasis, whereas dedifferentiated and pleomorphic types are more aggressive and prone to spreading to other organs.

Symptoms often include a painless, enlarging mass or swelling in the affected area, which can sometimes cause discomfort or functional impairment depending on its size and location. Diagnosis typically involves imaging studies such as MRI or CT scans, followed by a biopsy to confirm the cancer type and grade.

Treatment depends on the tumor's size, location, and subtype but usually involves surgical removal as the primary approach. Radiation therapy and chemotherapy may be used as adjuncts, especially in aggressive or advanced cases. Due to the risk of recurrence and metastasis, patients require close follow-up. Research continues into new therapies, including targeted treatments and immunotherapies, aiming to improve outcomes and reduce side effects.

Liposarcoma Emerging Drugs Profile

RAIN-32 (milademetan) is an orally administered small molecule that inhibits mouse double minute 2 (MDM2), a key regulator of the tumor suppressor protein p53, often called the "guardian of the genome." RAIN-32 is currently undergoing Phase III clinical trials for the treatment of liposarcoma.

Selinexor: Karyopharm Therapeutics

Selinexor is a novel, first-in-class selective inhibitor of nuclear export (SINE) that works by binding to and blocking the nuclear export protein XPO1. This inhibition causes tumor suppressor proteins to accumulate inside the cell nucleus. Marketed under the brand name XPOVIO, Selinexor has received US FDA approval for treating relapsed or refractory multiple myeloma, relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and in combination with bortezomib and dexamethasone for multiple myeloma patients who have had at least one prior therapy. It is also currently in Phase III trials for liposarcoma treatment

Discover the latest advancements in Liposarcoma treatment! Explore detailed insights on emerging therapies like RAIN-32 and Selinexor, currently in Phase III trials, and understand how they could transform patient care. Get your comprehensive report now to stay ahead in this evolving market and unlock new growth opportunities.- Liposarcoma Drugs and Therapies [https://www.delveinsight.com/report-store/liposarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Liposarcoma Pipeline Therapeutics Assessment

Around 15+ major companies are actively developing therapies for liposarcoma. Among them, Rain Therapeutics stands out with its liposarcoma drug candidates currently in the most advanced stage of development, Phase III.

Liposarcoma Pipeline Segmentation by Phases

- Late stage Liposarcoma products (Phase III)

- Mid-stage Liposarcoma products (Phase II)

- Early-stage Liposarcoma product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive Liposarcoma candidates

Liposarcoma Route of Administration

* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical

Liposarcoma Molecule Types

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type

Unlock in-depth insights into the Liposarcoma therapeutic landscape! Discover over 15 key companies, pipeline stages from early discovery to Phase III, diverse molecule types, and administration routes shaping the future of treatment. Download the full report now to identify emerging opportunities and stay competitive in this evolving market. @ Liposarcoma Treatment Algorithm [https://www.delveinsight.com/sample-request/liposarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Scope of the Liposarcoma Pipeline Report

* Coverage: Global
* Key Liposarcoma Companies include Karyopharm Therapeutics, Rain Therapeutics, Pfizer, Sanofi, Incyte Corporation, Macrogenics, Adaptimmune, Merck KGaA, GlaxoSmithKline, Novartis Oncology, Immune Design, Syndivia, TerSera Therapeutics, among others.
* The Liposarcoma Pipeline features therapies such as Trabectedin, Dexamethasone, Dacarbazine, RAIN-32, HDM201, LEE011, Selinexor, IPI-504, Yondelis, Cabazitaxel, MGCD516, and more.
* Pipeline segmentation includes categories based on product type, molecule type, mechanism of action, and route of administration.

Stay ahead in the global Liposarcoma market! Explore key players like Karyopharm, Rain Therapeutics, Pfizer, and others driving innovation with breakthrough therapies such as RAIN-32 and Selinexor. Get comprehensive pipeline insights segmented by product type, mechanism, and administration routes. Download our full report today to capitalize on emerging opportunities and accelerate your strategic growth! @ Liposarcoma Unmet Needs and Analyst Views [https://www.delveinsight.com/sample-request/liposarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Content

1. Introduction

2. Executive Summary

3. Liposarcoma: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Liposarcoma - DelveInsight's Analytical Perspective

7. Late Stage Products (Phase III)

8. RAIN-32: Rain Therapeutics

9. Drug profiles in the detailed report.....

10. Mid Stage Products (Phase II)

11. Cabazitaxel: Sanofi

12. Drug profiles in the detailed report.....

13. Early Stage Products (Phase I/II)

14. Ribociclib: Novartis Oncology

15. Drug profiles in the detailed report.....

16. Preclinical and Discovery Stage Products

17. SDV-1101: Syndivia

18. Drug profiles in the detailed report.....

19. Inactive Products

20. Liposarcoma Key Companies

21. Liposarcoma Key Products

22. Liposarcoma- Unmet Needs

23. Liposarcoma- Market Drivers and Barriers

24. Liposarcoma- Future Perspectives and Conclusion

25. Liposarcoma Analyst Views

26. Appendix

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=liposarcoma-pipeline-2025-clinical-trials-revenue-share-medication-treatment-drugs-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.